Tag Archives: Mirati Therapeutics

← Older posts

Amgen Doubles Down on BeiGene Collaboration, Investing $421M More

At the year’s start Thousand Oaks, CA-based Amgen closed a strategic collaboration with BeiGene, investing $2.8 billion to gain a presence in what’s becoming an ever-more essential market for global drug development. The investment earned it an R&D pact and ownership of about one-fifth of the Chinese oncology drug company. Now the firm has snapped […]

Posted in Boston blog main, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , | Comments Off on Amgen Doubles Down on BeiGene Collaboration, Investing $421M More

Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More

As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine. Moderna (NASDAQ: MRNA) moved one step closer to filling that need with the release of preliminary Phase […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

Cancer research is leading some companies to molecular targets that have eluded new medicines. Phase 1-ready biotech Black Diamond Therapeutics hopes its approach to such cancer targets leads it to the public markets. Black Diamond filed paperwork with securities regulators late Friday for an IPO. The Cambridge, MA-based firm set a $100 million goal for […]

Posted in Boston blog main, Boston top stories, Europe blog main, National blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , | Comments Off on Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex

The KRAS gene has become a hot target for cancer research for a growing number of drug developers. Merck, which is already testing a KRAS vaccine candidate, is now spreading its bets with a licensing deal for small molecule KRAS drugs being developed by two Otsuka Pharmaceutical subsidiaries. Merck (NYSE: MRK) is paying $25 million […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex

Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More

The brain has stymied many efforts to develop new neuroscience drugs, leading a number of big pharmaceutical companies to pull back on such R&D work. This week, Amgen joined them. Amgen (NASDAQ: AMGN) is ending its research and early development programs in neuroscience, the company announced during a conference call to discuss third-quarter financial results. […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

The European Society for Medical Oncology meeting has wrapped up in Barcelona, the last major clinical cancer conference until December’s annual ASH meeting for blood diseases. We’ve highlighted a few top stories for you. Amid all the fuss over cell, gene, and immunotherapies these days, an old-fashioned small-molecule class of drug called PARP inhibitors have […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

The treatment landscape for lung cancer has shifted significantly over the past few years, and more changes could be on the way. At the World Conference on Lung Cancer in Barcelona this weekend a number of drug makers trotted out some of their latest advances in immunotherapy, targeted pills, drug combinations, and more. Xconomy rounded […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

Mirati Stock Sale Targets $200M as Lead Cancer Drug Starts Phase 3

Mirati Therapeutics plans to raise more than $200 million this week in a public offering, funding that it plans to use to advance its lead cancer drug candidate, sitravatinib, into late-stage testing, and to continue developing its other targeted oncology programs. The San Diego company said Tuesday that it would sell 2.1 million shares of […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , | Comments Off on Mirati Stock Sale Targets $200M as Lead Cancer Drug Starts Phase 3

ASCO Abstracts: Breast Cancer, Precision Treatments in the Spotlight

The world’s biggest annual cancer conference is just around the corner. Data presented at the American Society of Clinical Oncology meeting each year can change medical practice and make or break companies whose drugs are under the microscope. That’s what makes even the “abstracts,” or snippets of data revealed a few weeks before the meeting, […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on ASCO Abstracts: Breast Cancer, Precision Treatments in the Spotlight

Science & Strategy Stars: Xconomy Awards San Diego Secret Weapon Finalists

[Updated 11:30 a.m. 5/16. See below.] Success in life sciences is always a team effort. Often, those doing the heavy lifting do so behind the scenes, without much external recognition of their role. To celebrate these hidden stars, we created the Secret Weapon category for the Xconomy Awards San Diego. The finalists in this category […]

Posted in Boston blog main | Tagged , , , , , , , , , , , , , , , , , | Comments Off on Science & Strategy Stars: Xconomy Awards San Diego Secret Weapon Finalists← Older posts